{"id":"mk0524a-duration-of-treatment-4-weeks","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MK0524A selectively binds to the GPR109A (niacin) receptor on immune cells and adipocytes, triggering signaling cascades that increase HDL-C production and reduce triglyceride levels. This mechanism mimics the beneficial lipid-modifying effects of niacin without the flushing side effects associated with direct niacin administration, as it avoids activation of GPR109B on keratinocytes.","oneSentence":"MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:44.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00533611","phase":"PHASE3","title":"Effect of MK0524A on Flushing Caused by Niacin (0524A-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Flushing","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0524A, /Duration of Treatment : 4 Weeks","genericName":"MK0524A, /Duration of Treatment : 4 Weeks","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides. Used for Dyslipidemia with low HDL-cholesterol and/or elevated triglycerides.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}